First seen Jul 2, 2026 · Updated 13h ago · 2 source items
Speculation about the next negotiation-eligible drug list is rebuilding, with policy analysts circulating probability-ranked candidate sets.
List inclusion materially changes long-term revenue models for affected franchises.
Moderate expected market impact (relevance 78/100). Most exposed: $MRK, $PFE, $BMY.
Updated my negotiation-list probability model. Two oncology franchises moved into the >70% bucket this round.
♥ 1.1K⇄ 340💬 150👁 162.0K
Analysts handicap the next drug-pricing negotiation round
Sell-side and policy analysts are converging on likely candidates for the next negotiation cycle.
1d ago · BioPharma Ledger
Analysts handicap the next drug-pricing negotiation round
17h ago · X
Updated my negotiation-list probability model. Two oncology franchises moved into the >70% bucket this round.
Moderate confidence (72/100), supported mainly by source credibility (70) and limited mainly by engagement depth (48).
Tickers
Agencies
Topics
Candidate lists are analyst speculation until CMS publishes; prior rounds surprised on composition.